In the spring, 2018 issue of MPDN, the drug INBRIJA was discussed (1).  INBRIJA is a self-administered, orally inhaled form of levodopa (similar to an asthma inhaler) which if approved by the Food and Drug Administration (FDA), will be indicated for symptoms of OFF periods in people who take carbidopa/levodopa for Parkinson’s disease.  In other … Continue reading FDA approval of inhaled levodopa delayed